pcos treatment glp-1 Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? | Journal of Endocrinological Investigation GLP-1 medications emerging as PCOS

Gastrointestinal: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction Hypersensitivity: anaphylaxis, angioedema Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation

That could shift

The GIP/GLP-1-receptor agonist tirzepatide was approved for the treatment of T2D by the Food and Drug Administration (FDA) in the USA for once-weekly subcutaneous injections in May 2022 and has just received a positive opinion from the European Medicines Agency (EMA)

Changtao Jiang (Peking University) and described previously 31

Rohm TV, Meier DT, Olefsky JM, Donath MY (2022) Inflammation in obesity, diabetes and related Disorders

This dual mechanism, weight-mediated and insulin-mediated aromatase reduction, may explain why some endometriosis patients see improvements that seem disproportionate to their weight loss alone